Glucose Control in Severely Burned Patients Using Metformin: An Interim Safety and Efficacy Analysis of a Phase II Randomized Controlled Trial

Objective: To determine whether metformin can achieve glucose control no worse than insulin (noninferiority) without the danger of hypoglycemia (superiority). In addition, to assess whether metformin has any additional effects on lipolysis and inflammation that will enhance burn recovery (superiority). Summary Background Data: Hyperglycemia and insulin resistance after burn injury are associated with increased morbidity and mortality. Insulin administration improves postburn infections, severity of sepsis, and morbidity, but also causes a 4–5-fold increase in hypoglycemia, which is associated with a 9-fold increase in mortality. Methods: Severely burned adult patients with burns over 20% total body surface area (TBSA) burn were prospectively randomized in this Phase II clinical trial to either metformin or insulin (standard of care) treatment. Primary outcomes were glucose levels and incidence of hypoglycemia. Secondary outcomes included glucose and fat metabolism, and clinical outcomes. Results: Forty-four patients were enrolled in this Phase II clinical trial, 18 metformin and 26 insulin patients. Demographics, burn size, concomitant injuries, and mortality were comparable between both groups. Metformin controlled blood glucose as equally as insulin with no difference between the 2 treatment groups, P > 0.05. While there was a 15% incidence of hypoglycemia in the insulin group, there was only 1 mild hypoglycemic episode (6%) in the metformin group, P < 0.05. Oral glucose tolerance tests at discharge revealed that metformin significantly improved insulin sensitivity, P < 0.05. Furthermore, metformin had a strong antilipolytic effect after burn injury when compared with insulin and was associated with significantly reduced inflammation, P < 0.05. Conclusions: Metformin decreases glucose equally as effective as insulin without causing hypoglycemia, with additional benefits including improved insulin resistance and decreased endogenous insulin synthesis when compared with insulin controls. These results indicate that metformin is safe in burn patients and further supports the use of metformin in severely burned patients for postburn control of hyperglycemia and insulin resistance.

[1]  D. Herndon,et al.  Hypoglycemia Is Associated With Increased Postburn Morbidity and Mortality in Pediatric Patients* , 2014, Critical care medicine.

[2]  R. Grieve,et al.  A randomized trial of hyperglycemic control in pediatric intensive care. , 2014, The New England journal of medicine.

[3]  C. Finnerty,et al.  Wound Coverage Technologies in Burn Care: Novel Techniques , 2013, Journal of burn care & research : official publication of the American Burn Association.

[4]  D. Herndon,et al.  Optimized fluid management improves outcomes of pediatric burn patients. , 2013, The Journal of surgical research.

[5]  D. Herndon,et al.  Effects of Metformin on Burn-Induced Hepatic Endoplasmic Reticulum Stress in Male Rats , 2013, Molecular Medicine.

[6]  B. Viollet,et al.  Biguanides suppress hepatic glucagon signaling by decreasing production of cyclic AMP , 2016 .

[7]  Robert Kraft,et al.  Burn size and survival probability in paediatric patients in modern burn care: a prospective observational cohort study , 2012, The Lancet.

[8]  D. Herndon,et al.  Long-Term Persistance of the Pathophysiologic Response to Severe Burn Injury , 2011, PloS one.

[9]  D. Herndon,et al.  Glucose Control in Severely Thermally Injured Pediatric Patients: What Glucose Range Should Be the Target? , 2010, Annals of surgery.

[10]  D. Herndon,et al.  Intensive insulin therapy in severely burned pediatric patients: a prospective randomized trial. , 2010, American journal of respiratory and critical care medicine.

[11]  Michael Bailey,et al.  Hypoglycemia and outcome in critically ill patients. , 2010, Mayo Clinic proceedings.

[12]  Taufiq Rahman,et al.  Regulation of Inositol 1,4,5-Trisphosphate Receptors by cAMP Independent of cAMP-dependent Protein Kinase , 2010, The Journal of Biological Chemistry.

[13]  S. Arbabi,et al.  Intensive insulin therapy is associated with reduced infectious complications in burn patients. , 2008, Surgery.

[14]  R. Gamelli,et al.  Temporal Cytokine Profiles in Severely Burned Patients: A Comparison of Adults and Children , 2008, Molecular medicine.

[15]  D. Chinkes,et al.  Pathophysiologic Response to Severe Burn Injury , 2008, Annals of surgery.

[16]  D. Herndon,et al.  Gender Differences in Pediatric Burn Patients: Does It Make a Difference? , 2008, Annals of surgery.

[17]  D. Herndon,et al.  Are serum cytokines early predictors for the outcome of burn patients with inhalation injuries who do not survive? , 2008, Critical care.

[18]  D. Herndon,et al.  Abnormal insulin sensitivity persists up to three years in pediatric patients post-burn. , 2009, The Journal of clinical endocrinology and metabolism.

[19]  R. Gamelli,et al.  American Burn Association Consensus Conference to Define Sepsis and Infection in Burns , 2007, Journal of burn care & research : official publication of the American Burn Association.

[20]  R. Holt,et al.  The addition of metformin in type 1 diabetes improves insulin sensitivity, diabetic control, body composition and patient well‐being , 2007, Diabetes, obesity & metabolism.

[21]  D. Chinkes,et al.  SERUM CYTOKINE DIFFERENCES IN SEVERELY BURNED CHILDREN WITH AND WITHOUT SEPSIS , 2007, Shock.

[22]  D. Hardie.  Neither LKB1 nor AMPK are the direct targets of metformin. , 2006, Gastroenterology.

[23]  B. Staels.  Metformin and pioglitazone: effectively treating insulin resistance , 2006, Current medical research and opinion.

[24]  G. Rutter,et al.  Expanding role of AMPK in endocrinology , 2006, Trends in Endocrinology & Metabolism.

[25]  C. Finnerty,et al.  Burn size determines the inflammatory and hypermetabolic response , 2006, Critical care.

[26]  N. Musi.  AMP-activated protein kinase and type 2 diabetes. , 2006, Current medicinal chemistry.

[27]  L. Goodyear,et al.  Insulin resistance and improvements in signal transduction , 2006, Endocrine.

[28]  R. Barrow,et al.  The Use of Beta-Adrenergic Blockade in Preventing Trauma-Induced Hepatomegaly , 2006, Annals of surgery.

[29]  D. Greenhalgh,et al.  Impact of tight glycemic control in severely burned children. , 2005, The Journal of trauma.

[30]  R. Wolfe,et al.  Influence of Metformin on Glucose Intolerance and Muscle Catabolism Following Severe Burn Injury , 2005, Annals of surgery.

[31]  J. Yates,et al.  The CREB Coactivator TORC2 Functions as a Calcium- and cAMP-Sensitive Coincidence Detector , 2004, Cell.

[32]  R. Horch,et al.  Insulin Treatment Improves Hepatic Morphology and Function Through Modulation of Hepatic Signals After Severe Trauma , 2004, Annals of surgery.

[33]  Dagmar Klein,et al.  Insulin Treatment Improves the Systemic Inflammatory Reaction to Severe Trauma , 2004, Annals of surgery.

[34]  R. Wolfe,et al.  Metformin blunts stress-induced hyperglycemia after thermal injury. , 2003, The Journal of trauma.

[35]  Steven E Wolf,et al.  Hyperglycemia exacerbates muscle protein catabolism in burn-injured patients , 2002, Critical care medicine.

[36]  R. Wolfe,et al.  Propranolol Decreases Splanchnic Triacylglycerol Storage in Burn Patients Receiving a High-Carbohydrate Diet , 2002, Annals of surgery.

[37]  K. Nair,et al.  Effects of free fatty acids and glycerol on splanchnic glucose metabolism and insulin extraction in nondiabetic humans. , 2002, Diabetes.

[38]  G. V. Berghe,et al.  Intensive insulin therapy in critically ill patients. , 2001, The New England journal of medicine.

[39]  Margaret S. Wu,et al.  Role of AMP-activated protein kinase in mechanism of metformin action. , 2001, The Journal of clinical investigation.

[40]  D. Chinkes,et al.  Association of hyperglycemia with increased mortality after severe burn injury. , 2001, The Journal of trauma.

[41]  K. Petersen,et al.  Mechanism by which metformin reduces glucose production in type 2 diabetes. , 2000, Diabetes.

[42]  V. Jensen,et al.  Phosphorylation of the Inositol 1,4,5-Trisphosphate Receptor by Cyclic Nucleotide-dependent Kinases in Vitroand in Rat Cerebellar Slices in Situ * , 1999, The Journal of Biological Chemistry.

[43]  D L Rothman,et al.  Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. , 1999, The Journal of clinical investigation.

[44]  G Dailey,et al.  Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. , 1995, The New England journal of medicine.

[45]  G. Biolo,et al.  Lipolysis in burned patients is stimulated by the beta 2-receptor for catecholamines. , 1994, Archives of surgery.

[46]  L. Rossetti,et al.  Mechanisms of fatty acid-induced inhibition of glucose uptake. , 1994, The Journal of clinical investigation.

[47]  Lawrence A Leiter,et al.  Cellular mechanism of metformin action involves glucose transporter translocation from an intracellular pool to the plasma membrane in L6 muscle cells. , 1992, Endocrinology.

[48]  R. Wolfe,et al.  Effect of severe burn injury on substrate cycling by glucose and fatty acids. , 1987, The New England journal of medicine.

[49]  R. Wolfe,et al.  Regulation of Lipolysis in Severely Burned Children , 1987, Annals of surgery.

[50]  E. Newsholme,et al.  The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. , 1963, Lancet.

[51]  J. Pankow,et al.  Fasting plasma free fatty acids and risk of type 2 diabetes: the atherosclerosis risk in communities study. , 2004, Diabetes care.

[52]  Larry E Wagner,et al.  Modulation of cytosolic calcium signaling by protein kinase A-mediated phosphorylation of inositol 1,4,5-trisphosphate receptors. , 2004, Biological research.

[53]  S. Inzucchi,et al.  Metformin: new understandings, new uses. , 2003, Drugs.